Could a single lens implant replace daily eye drops for glaucoma?

NCT ID NCT07154810

Ongoing Disease control Sponsor: SpyGlass Pharma, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study follows 23 people who received a special lens implant that slowly releases a glaucoma drug (bimatoprost) during cataract surgery. Researchers want to see if it keeps eye pressure low and vision clear for up to 7 years. The goal is to learn whether this combination device can safely treat both cataracts and glaucoma long-term.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bimatoprost implant combined with a special intraocular lens
What this could lead to: If successful, this could show that a single implant can control eye pressure and improve vision for years, reducing the need for daily eye drops.
What could go wrong: This is a small, observational follow-up study with only 23 participants, so results may not apply to everyone. Long-term safety and effectiveness are still being checked.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CATARACT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cataract glaucoma ocular hypertension open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CATARACT GLAUCOMA OCULAR HYPERTENSION

Contacts and locations

Locations

Centro Oftalmológico Robles

Santa Rosa de Copán, 41101, Honduras

More trials for these conditions

Other studies related to the condition(s) this trial covers.